New Depression Treatments: Alternatives to Antidepressants

Standard antidepressants — SSRIs, SNRIs, and related classes — help many people, but a meaningful share of patients don't get adequate relief even after trying more than one. If that describes you, there are several established and emerging paths beyond another medication trial. This page is a plain overview of what's actually available, what's FDA-approved versus off-label or still investigational, and who typically considers each one — not a ranking of "best" treatments. Each section routes to a deeper page on this site or elsewhere for the specifics; the goal here is helping you narrow down what to ask a psychiatric provider about first.

Options below are grouped by how established they are — FDA-approved and FDA-cleared treatments first, then procedure-based options with a longer track record, then additions and investigational directions worth knowing about but not mistaken for first-line care. None of this is medical advice, and no page substitutes for a psychiatric evaluation of your specific diagnosis and history.

When Antidepressants Haven't Worked: Treatment-Resistant Depression

Before exploring alternatives, it helps to know where you actually stand clinically. Treatment-resistant depression has a specific definition — an inadequate response to two or more antidepressants, each given at an adequate dose for an adequate length of time. That distinction matters because most of the options below, including Spravato's FDA approval, are studied and labeled specifically for that population, not for anyone who simply feels their current medication isn't working well enough yet. A psychiatric provider is who determines whether you meet that threshold, typically by reviewing which medications you've tried, at what doses, and for how long.

That documentation step is easy to skip but worth doing carefully, since it's what most of the treatments below are actually studied and, in some cases, FDA-labeled for. Stopping one antidepressant after two weeks due to side effects isn't an adequate trial in the clinical sense, even if it feels like "nothing has worked"; three full-dose, full-duration medications from different classes without relief is a clearer fit. Bringing a written timeline of what you've tried — medication, dose, duration, outcome — to an evaluation speeds this part up considerably.

Ketamine Therapy (IV and IM Ketamine)

Ketamine is a dissociative anesthetic that, at the low doses used for depression, appears to work through a different brain pathway than SSRIs or SNRIs — blocking NMDA glutamate receptors rather than acting on serotonin or norepinephrine. Clinics deliver it as an IV infusion over 40 to 60 minutes, or as a simpler IM (intramuscular) injection. Generic ketamine has no FDA approval for depression — it's approved only as a surgical anesthetic, so mental-health use is entirely off-label, prescribed at a physician's discretion. A typical course is an induction series of six infusions over two to three weeks, followed by periodic boosters, and every session requires a monitored recovery period and a driver home. People considering it are often those who want faster symptom movement than a medication trial offers, or who don't have access to a Spravato-certified clinic. For the fuller evidence picture, including who tends to benefit and how durable the effect is, see does ketamine therapy work for depression.

Because it's off-label, insurance rarely covers the treatment itself, so most patients self-pay per infusion, though some clinics issue superbills for out-of-network reimbursement attempts. Screening before the first session typically covers cardiovascular history, current blood pressure control, and personal or family history of psychosis, since ketamine is generally avoided in that last group. Some telehealth programs also prescribe oral ketamine troches for at-home use, which produce lower peak blood levels and involve less direct oversight than a clinic-administered infusion or injection — worth understanding as a distinct, lower-intensity option rather than assuming it carries the same evidence base as infusion therapy.

Spravato (Esketamine) Nasal Spray

Spravato is a nasal spray form of esketamine — one mirror-image molecule isolated from ketamine — and it's the option most directly answering searches for a nasal spray for depression. Unlike generic ketamine, it carries direct FDA approval: first for treatment-resistant depression in 2019, then for depressive symptoms in adults with suicidal thoughts, always used alongside an oral antidepressant rather than alone. It's self-administered under staff supervision at a REMS-certified clinic, with about two hours of monitored observation afterward, and dosing typically runs twice weekly for the first month before tapering to a maintenance schedule. Because it's FDA-approved for this specific indication, it's more often covered by insurance with prior authorization than generic ketamine, which is a major reason many patients start there. See the Spravato (esketamine) treatment page for dosing, cost, and provider details.

Spravato isn't self-administered at home the way an ordinary nasal spray is — patients use it under direct staff observation and remain at the clinic for the full monitoring window because of possible sedation, dissociation, and a temporary rise in blood pressure. Common candidates are patients who already meet the treatment-resistant definition, want a fixed and predictable dosing structure rather than an infusion's adjustable rate, and have insurance likely to cover an FDA-approved indication. Patients who need more dose flexibility, or who are being treated for a condition outside Spravato's approved label, more often end up considering IV ketamine instead.

Transcranial Magnetic Stimulation (TMS)

TMS uses a magnetic coil against the scalp to stimulate a brain region tied to mood regulation, with no drug entering the bloodstream and no sedation — patients stay alert and can drive themselves home after each session. It's FDA-cleared as a medical device for major depressive disorder and for OCD, with broader insurance coverage than generic ketamine in most cases. The tradeoff is time: a standard course is five sessions a week for about six weeks, 30 or more individual visits. People who can commit to that schedule, want to avoid dissociative effects entirely, or need to drive themselves to and from treatment often consider TMS before or alongside ketamine-based options. A full head-to-head on mechanism, timelines, cost, and how to decide between the two is covered in ketamine therapy vs. TMS for depression.

TMS's screening questions center on metal implants or devices near the head, such as certain pacemakers, and any personal history of seizures, since the treatment carries a rare seizure risk. Most patients tolerate it well after an initial adjustment period; the sensation is a tapping or knocking feeling at the treatment site along with the coil's clicking sound, and clinics adjust pulse intensity for comfort. Its longer FDA history and broader insurance coverage make it a common first stop for patients whose documented treatment history and insurance plan support it, though the daily schedule is a genuine barrier for people who can't take that much time during the workday over six consecutive weeks.

Electroconvulsive Therapy (ECT)

ECT delivers a brief, controlled electrical stimulus to the brain under general anesthesia, inducing a short seizure that produces changes in brain chemistry and circuitry linked to mood improvement. It's an FDA-regulated medical procedure with decades of clinical use, and it remains one of the most effective treatments for severe or treatment-resistant depression, including cases with psychotic features or acute suicidality where a fast, high-response-rate option is needed. A course usually runs two to three sessions a week for several weeks, each requiring anesthesia and a recovery period, and short-term memory effects around the treatment period are a known consideration discussed with patients beforehand. ECT is generally considered later in a treatment sequence, or earlier when severity demands it, and always through a psychiatric team experienced in administering it — not something to pursue without that evaluation.

Vagus Nerve Stimulation (VNS)

VNS uses a small surgically implanted device that sends regular electrical pulses to the vagus nerve, which has connections to brain regions involved in mood regulation. It's FDA-approved specifically for chronic or recurrent treatment-resistant depression in adults who haven't responded to four or more prior treatments — a narrower, later-line indication than ketamine, Spravato, or TMS. Because it requires a surgical procedure and its effects build gradually over months rather than weeks, it's typically considered only after other options have been tried without adequate relief, and it's evaluated by a specialist team rather than a general psychiatric practice. Response can take six months to a year to become fully apparent, which is a very different timeline than any other option on this page — patients weighing VNS are usually doing so because faster options have already been exhausted, not as an alternative to trying them first.

Ketamine-Assisted Psychotherapy and Other Talk-Therapy Additions

Some clinics pair a ketamine dose with structured psychotherapy sessions — before, during, or shortly after the dissociative window — under the idea that the drug's effects may make patients more receptive to therapeutic work. This is usually called ketamine-assisted psychotherapy, and it's offered alongside, not instead of, standard IV or IM ketamine protocols. More broadly, evidence-based psychotherapies such as CBT are commonly added to any of the treatments on this page rather than used as a standalone alternative for depression that hasn't responded to medication alone — most psychiatric guidance treats medication or procedure-based treatment and therapy as complementary, not either/or.

What this looks like varies by clinic — some have a licensed therapist present during the dosing session, others schedule integration sessions afterward, and some do both. There's no single standardized protocol, so ask a prospective clinic who provides the therapy component, whether that person is licensed, and how it's billed, since it's sometimes charged separately from the medical dosing visit.

Lifestyle Changes: A Useful Adjunct, Not a Replacement

Sleep regularity, physical activity, and reducing alcohol use are frequently discussed alongside depression treatment, and there's reasonable clinical support for exercise and sleep improvements helping mood and supporting recovery. Being honest about scope matters here: for depression that has already resisted two or more adequately dosed antidepressants, lifestyle changes alone are not a substitute for the treatments above, and no reputable source claims they are. They're worth pursuing as a complement to whatever treatment you and your provider choose, not as a first-line answer to treatment resistance.

Being specific helps: regular aerobic exercise has some of the better clinical support among adjuncts, consistent sleep and wake times can matter as much as erratic sleep works against mood, and reducing alcohol counts because alcohol can blunt antidepressant effectiveness and interacts with several treatments above, including sedation risk around ketamine and Spravato sessions. These remain supportive measures a clinician may fold into a plan, not a standalone response to depression that has already resisted medication.

Investigational Directions: Psilocybin and What's Still Being Studied

Psilocybin, the active compound in certain mushrooms, is being studied in clinical trials for treatment-resistant depression, alongside other psychedelic-assisted approaches. It is not FDA-approved for depression or any other condition, and it remains a Schedule I controlled substance federally, though a small number of states and cities have created limited decriminalized or regulated access outside standard FDA channels. Trial results published so far are early, oversight and screening protocols vary widely outside a controlled study, and anyone considering it should treat it as investigational — not an established treatment on par with the FDA-approved or FDA-cleared options above — and discuss it openly with a psychiatric provider rather than pursuing it independently.

Other compounds and delivery methods are in earlier research stages for depression too. What separates an investigational option from the treatments above isn't promise or publicity — it's the amount of peer-reviewed, controlled trial evidence behind it, and whether that evidence has cleared the FDA's approval bar. A program offering an investigational treatment outside a registered clinical trial deserves real caution, since the usual layers of trial oversight and outcome tracking may not apply.

Options at a Glance

How to Start Narrowing Down Your Options

A useful first conversation with a psychiatric provider covers three things: whether your depression meets the treatment-resistant definition, what your insurance actually covers among these options, and how much time and monitoring you can realistically commit to. Someone who can't take five weeks of near-daily appointments may lean toward ketamine or Spravato's more compressed schedule; someone who wants to avoid dissociative effects or an IV line may lean toward TMS; someone in acute crisis with severe symptoms may need ECT evaluated sooner rather than later. None of that is a substitute for an actual psychiatric evaluation of your history, current symptoms, and medical background.

• Documented treatment history: confirms whether you meet the treatment-resistant threshold most of these options are studied and, in some cases, labeled for.
• Insurance and cost: Spravato and TMS are more consistently covered with prior authorization; generic IV/IM ketamine is usually self-pay; ECT and VNS coverage varies by plan and clinical severity.
• Time and transportation: a five-times-weekly TMS schedule, a multi-week ketamine induction series with a required driver, and a surgical VNS evaluation all ask very different things of your calendar.
• Symptom severity and urgency: acute crisis, suicidality, or psychotic features tend to accelerate evaluation for faster-acting or higher-response-rate options like ketamine, Spravato, or ECT.
• Tolerance for the procedure itself: some patients are more averse to dissociation and an IV line than to a magnetic coil or a surgical implant, and the reverse is also common.

If ketamine or Spravato looks like a direction worth exploring after weighing those factors, the ketamine clinic directory lists providers by state and by which formats they offer, so you can compare options near you before scheduling a consultation.

Frequently Asked Questions

Informational only — not medical advice. Discuss treatment selection with a licensed psychiatric provider who knows your treatment history and current diagnosis.